期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

乳腺癌的化疗方案 被引量：4

下载PDF
导出
摘要 乳腺癌是女性常见的恶性肿瘤,目前治疗方法采用以手术为主的综合治疗方案,并强调个体化。雌激素受体（ER）与人类表皮生长因子受体2（HER-2）是影响乳腺癌预后的2个非常重要的生物学指标,两者并不同时在乳腺癌组织中表达。
作者 涂小煌
机构地区 解放军南京军区福州总医院普通外科研究所
出处 《中国临床医生杂志》 2011年第7期9-11,共3页 Chinese Journal For Clinicians
关键词 乳腺癌预后 化疗方案 人类表皮生长因子受体 综合治疗方案 以手术为主 生物学指标 雌激素受体 乳腺癌组织
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献10

  • 1Schlag PM, Benhidje B. Hyperthermic radiochemotherapy for e- sophageal cancer rationale and conception of phase In trim [ J ]. Onkologie, 1999,22 (91 ) : 48 - 55.
  • 2Dowsett M, Ebbs SR, Dixon JM, et al. Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination : influence of hormonal status and HER-2 in breast cancer a study from the IMPACT trialists [ J]. ClinOnco1,2005,23 ( 11 ) : 2477 - 2492.
  • 3Rakha EA, E1-Sayed ME, Green A. Prognostic marker intriple- negative breast cancer[ J]. Cancer,2007,109 ( 1 ) : 25 - 29.
  • 4Torrisi R,Balduzzi A,Ghisini R,et al. Tailored preoperative treat- ment of locally advanced triple negative( hormone receptor negative and HER2 negative) breast cancer with epirubicin, eieplatin, and infusional fluorouracil followed by weekly paclitaxel [ J ]. Cancer Chemother Pharmaeol, 2008,62 ( 4 ) : 667 - 669.
  • 5Gradishar WJ, Tjutandin S, Davidson N, et al. Phase 3 Trial of nanoparticle albumin-bound compared with polyethylated castor oil-based paclitaxel in women with breast cancer [ J ]. Clin On- col ,2005,23 (31) : 7794 -7803.
  • 6Gholam D, Chebib A, Hanteville D, et al. Combined paclitaxel and cetuximab achieved a major, response on the skinmetastases of a patient with epidermal growth factor receptor-positive, estro- gen receptor-negative, progesterone receptor-negative and human epidermal growth factor receptor-2-negative (triple-negative) breast Cancer[ J ]. Anticancer Drugs,2007,18 ( 7 ) : 835 - 838.
  • 7Bria E,Nistico C,Cuppone F,et al. Benefit of taxanes as adju- vant chemotherapy for early breast cancer: pooled analysis of 15 500 patients [ J ]. Cancer, 2006,106 ( 11 ) : 2337 - 2344.
  • 8Ferguson T, Wilcken N, Vagg R, et al. Taxanes for adjuvant treat- ment of early breast cancer[ J ]. Cochrane Database of Systematic Reviews 2007, (4) : 475 - 478.
  • 9Sparano J, Wang M, Martino S, et al. Weekly paclitaxel in the ad- juvant treatment of breast cancer [ J 3. N Engl J Med, 2008,358 ( 16): 1663 - 1671.
  • 10Quill T, Abair T, Garcia K, et al. The american society of clinical oncology 2009 breast cancer symposium [ J ]. Clin Breast Canc- er,2009,9 (4) : 213 - 218.

同被引文献38

  • 1Beata B, Joanna N. Prognostic potential of topoisomerase IIa and HER-2 in a retrospective analysis of early advanced breast caneer patients treated with adjuvant anthracycline chemotherapy[ J ]. Breast,2011,3 : 1-13.
  • 2Van Dongen JA, Voogd AC, Fentinan IS, et al. Long-term results of a randomized trial comparing breast conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer [ J ]. Trial, 2000,92 ( 14 ) : 1143- 1150.
  • 3Goldhirsch A, Ingle JN, Gelber RD, et al. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2009[J]. Annals of Oncology , 2009,20(8) :1319-1329.
  • 4胡夕春,王碧芸.转移性乳腺癌内科治疗进展[J].中国临床肿瘤学进展,2010,8:281-283.
  • 5Voravud N, Phase II trial of ramosetron plus dexamethaso- nein the prevention of cisplatin-induced nausea and vomiting [ J]. MedAssoc Thai ,2005, 88 (12) : 1790-1796.
  • 6Larrey D, Pageaux GP. Drug-induced acute liver failure [ J ]. Eur J Gastroenterol Hepatol,2005,17 : 141-143.
  • 7Kosmas C, Kallistratos M, Kopterides P, et al. Cardiotoxici- ty of fluoropyrinidines in different schedules of administra- tion: a prospective study[ J ]. J Cancer Res Clin Oncol,2008, 134 : 75-82.
  • 8徐兵河.复发转移乳腺癌的化学治疗[J].中国实用内科杂志,2007,27(24):1913-1916. 被引量：20
  • 9Balslev I, Axelsson C K, Zedeler K, et al. The Notting- ham Prognostic Index applied to 9,149 patients from the studies of the Danish Breast Cancer Cooperative Group (DBCG) [J~, Breast Cancer Res Treat, 1994, 32 (3) :281-290.
  • 10Burness M L, Grushko T A, Olopade O I. Epidermal growth factor receptor in triple-negative and basal-like breast cancer: promising clinical target or only a mark- er~J]. Cancer J, 2010, 16(1 ) :23-32.

引证文献4

二级引证文献16

中国临床医生杂志
2011年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部